Sign In
Buy NDAQ
$82.49
-0.120 (-0.145%)
At Close: Jun 23, 2026
Why the Nasdaq Is Is Now Up Big Today (NVDA, DASH, PLTR)
05:30pm, Wednesday, 02'nd Apr 2025
24/7 Wall St.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Wednesday, 02'nd Apr 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 02'nd Apr 2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Wednesday, 02'nd Apr 2025
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 02'nd Apr 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 02'nd Apr 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Tradeweb, Nasdaq, Virtu, ICE, BGC Group, Cboe Set To Benefit From IPO Comeback: Analyst
03:02pm, Wednesday, 02'nd Apr 2025
Macro uncertainty has delayed the timeline for an IPO comeback, but there remains substantial pent-up supply for equity issuance.
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
01:20pm, Wednesday, 02'nd Apr 2025
FORT LAUDERDALE, FL / ACCESS Newswire / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of t
C3is Inc. Announces Reverse Stock Split
09:00am, Wednesday, 02'nd Apr 2025
To be effective April 4, 2025 Aiming to meet the minimum bid price requirement for maintaining listing on Nasdaq ATHENS, Greece, April 02, 2025 (GLOBE NEWSWIRE) -- C3is Inc. (the “Company”) (Nasda
Heidmar Joins Nasdaq for Closing Bell
08:15am, Wednesday, 02'nd Apr 2025
ATHENS, Greece and NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Heidmar Maritime Holdings Corp. (“Heidmar”) (NASDAQ: HMR), is pleased to announce that its senior leadership team will ring the Nasd
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 02'nd Apr 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted ten newl
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 02'nd Apr 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 01'st Apr 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1
Syra Health Announces Voluntary Delisting from the Nasdaq Capital Market
05:00pm, Tuesday, 01'st Apr 2025
CARMEL, Ind., April 1, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative t
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Tuesday, 01'st Apr 2025
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
